ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO110

Circulating Cell Free DNA Is Associated with Dynamics in FOXP3 Expression in Peripheral CD4+CD25+CD127+ T Cells in Patients with Lupus Nephritis

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders

Authors

  • Foroncewicz, Bartosz, Medical University of Warsaw, Warsaw, Poland
  • Mucha, Krzysztof, Medical University of Warsaw, Warsaw, Poland
  • Bocian, Katarzyna, University of Warsaw, Faculty of Biology, Warsaw, Poland
  • Zagozdzon, Radoslaw, Medical University of Warsaw, Warsaw, Poland
  • Wirkowska, Agnieszka, Medical University of Warsaw, Warsaw, Poland
  • Truszewska, Anna, Medical University of Warsaw, Warsaw, Poland
  • Kaminska, Joanna, West Hospital of Saint Paul II, Grodzisk Mazowiecki, Poland
  • Moszczuk, Barbara, Medical University of Warsaw, Warsaw, Poland
  • Korczak-Kowalska, Gra?yna, University of Warsaw, Faculty of Biology, Warsaw, Poland
  • Paczek, Leszek, Medical University of Warsaw, Warsaw, Poland
Background

Lupus nephritis (LN) is a manifestation of systemic lupus erythematosus (SLE) associated with poor outcome. The pathophysiology of LN is multifactorial and the search continues for a set of suitable biomarkers to assess the status of the disease. Recently, attention has been drawn to abnormally elevated circulating cell free DNA (cfDNA) as a potential biomarker of SLE progression towards LN. However, it is unclear how concentrations of cfDNA correlate with the pattern and changes within functional subpopulations of T cells in LN patients. We carried our such an assessment in our study.

Methods

Forty eight LN patients were enrolled. Their blood was collected twice: at baseline and after six months for biochemical tests and biomarker evaluation. Flow cytometry was used for analysis of T cells populations for the expression of CD4, CD25, CD127 and intracellular FOXP3. cfDNA was isolated by use of QIAamp Circulating Nucleic Acid Kit (QIAGEN, Hilden, Germany).

Results

We found significant associations between cfDNA concentrations at baseline and also cfDNA change over six months with the changes in intracellular FOXP3 content in subpopulation of CD4(+)CD25(+)CD127(+) T cells.

Conclusion

CD4(+)CD25(+)CD127(+)FoxP3(+) subpopulation of T cells has been proposed to act as a suppressor of autoimmunity. The exact biomarker potential of this subpopulation of T cells in autoimmune diseases, including LN, has not been fully explored. Our study suggests that this particular subpopulation of T cells may become useful as an attractive indicator of disease activity in LN, which warrants further investigation.

Funding

  • Government Support - Non-U.S.